Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 9/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.35 |
| ▸ | CDK9 | P50750 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750547 | 1.00 | CLK1 (0.47) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL524746 | 0.79 | ALDH1A1 (0.46) | MAPT | |
| SCHEMBL16357 | 0.79 | KDM4E (0.32) | CLK1CSNK1DCSNK1EDYRK1A | |
| SCHEMBL16316 | 0.79 | MAP4K4 (0.34) | CLK1CSNK1DCSNK1EDYRK1A | |
| SCHEMBL2139252 | 0.77 | ALDH1A1 (0.44) | MAPT | |
| SCHEMBL4036768 | 0.76 | CLK1 (0.57) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL445516 | 0.76 | CLK1 (0.57) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156508 | 0.73 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156497 | 0.73 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156496 | 0.73 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008130515-A1 | ANTI-CANCER AGENTS, COMPOSITIONS AND METHODS OF TREATING CANCERS | ACB, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080255175-A1 | Anti-cancer agents, compositions and methods of treating cancers | ACB, LLC | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255175-A1 | Anti-cancer agents, compositions and methods of treating cancers | HCCS, EPOR, RAD51 | CLK1 4719/4885CSNK1D 1174/4885CSNK1E 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.